4//SEC Filing
IDENIX PHARMACEUTICALS INC 4
Accession 0001209191-14-050676
CIK 0001093649operating
Filed
Aug 4, 8:00 PM ET
Accepted
Aug 5, 5:38 PM ET
Size
25.6 KB
Accession
0001209191-14-050676
Insider Transaction Report
Form 4
Mayers Douglas L
EVP and Chief Medical Officer
Transactions
- Disposition to Issuer
Stock Option (Right to Buy)
2014-08-05−100,000→ 0 totalExercise: $8.88Exp: 2017-01-21→ Common Stock (100,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2014-08-05−80,000→ 0 totalExercise: $5.18Exp: 2018-02-21→ Common Stock (80,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2014-08-05−40,000→ 0 totalExercise: $5.46Exp: 2019-02-12→ Common Stock (40,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2014-08-05−60,000→ 0 totalExercise: $3.17Exp: 2021-02-20→ Common Stock (60,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2014-08-05−120,000→ 0 totalExercise: $4.65Exp: 2023-02-19→ Common Stock (120,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2014-08-05−100,000→ 0 totalExercise: $7.01Exp: 2024-02-09→ Common Stock (100,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2014-08-05−40,000→ 0 totalExercise: $2.41Exp: 2017-11-08→ Common Stock (40,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2014-08-05−40,000→ 0 totalExercise: $2.96Exp: 2020-02-09→ Common Stock (40,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2014-08-05−125,000→ 0 totalExercise: $12.08Exp: 2022-02-28→ Common Stock (125,000 underlying)
Footnotes (9)
- [F1]These options, which vested in 48 equal monthly installments beginning on January 31, 2007, were cancelled pursuant to the Agreement and Plan of Merger between the Issuer and Merck & Co. Inc. (the "Merger Agreement") in exchange for a cash payment of $15.62 per share, representing the difference between the exercise price of the options and $24.50 per share.
- [F2]These options, which vested in 48 equal monthly installments beginning on November 30, 2007, were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $22.09 per share, representing the difference between the exercise price of the options and $24.50 per share.
- [F3]These options, which vested in 48 equal monthly installments beginning on February 29, 2008, were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $19.32 per share, representing the difference between the exercise price of the options and $24.50 per share.
- [F4]These options, which vested in 48 equal monthly installments beginning on February 28, 2009, were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $19.04 per share, representing the difference between the exercise price of the options and $24.50 per share.
- [F5]These options, which vested in 48 equal monthly installments beginning on February 28, 2010, were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $21.54 per share, representing the difference between the exercise price of the options and $24.50 per share.
- [F6]These options, which vested in 48 equal monthly installments beginning on February 28, 2011, were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $21.33 per share, representing the difference between the exercise price of the options and $24.50 per share.
- [F7]These options, which vested in 48 equal monthly installments beginning on February 29, 2012, were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $12.42 per share, representing the difference between the exercise price of the options and $24.50 per share.
- [F8]These options, which vested in 48 equal monthly installments beginning on February 28, 2013, were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $19.85 per share, representing the difference between the exercise price of the options and $24.50 per share.
- [F9]These options, which vested in 48 equal monthly installments beginning on February 28, 2014, were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $17.49 per share, representing the difference between the exercise price of the options and $24.50 per share.
Documents
Issuer
IDENIX PHARMACEUTICALS INC
CIK 0001093649
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001093649
Filing Metadata
- Form type
- 4
- Filed
- Aug 4, 8:00 PM ET
- Accepted
- Aug 5, 5:38 PM ET
- Size
- 25.6 KB